Viatris Closes $1.65 Billion Pacira Deal for Non-Opioid Pain Medicines
Viatris announced on November 17, 2026, that it had completed its acquisition of Pacira BioSciences for $36.50 per share in cash, without interest and net of applicable withholding taxes. The October 8, 2026, agreement valued the transaction at $1.65 billion in aggregate equity. The acquisition adds two marketed U.S. pain treatments: EXPAREL, a long-acting local analgesic used for postsurgical pain management, and ZILRETTA, an extended-release intra-articular injection indicated for…